Ligand-based drug design combines AI and QSAR modeling to prioritize drug candidates, minimizing preclinical failures and ...

Sphingosine-1-phosphate receptors are the targets for treating many human diseases and selectivity is one of the major hindrances during drug development. Two crystal structures of human sphingosine-1 ...

$15 million payment fulfills previously scheduled tranche under royalty-based financing agreement, bringing total capital received from Ligand to $40 million to date in exchange for tiered royalty ...

Acquisition is expected to be immediately accretive to Ligand adjusted EPS; Ligand increases 2026 adjusted EPS guidance to $8.50-$9.501 and expects the transaction to be accretive by $1.50 per share ...

Funding supports continued execution of Orchestra BioMed's pivotal trials for Atrioventricular Interval Modulation Therapy ("AVIM Therapy") and Virtue Sirolimus AngioInfusion Balloon ("Virtue SAB") ...

Lead Radio-DARPin MP0712 progressing in Phase 1/2a trial with multiple clinical sites opening and initial clinical data expected in 2026New data on Radio-DARPins’ amenability to range of therapeutic ...

Payment fulfills previously disclosed funding commitment of $20 million and supports planned completion of the BACKBEAT Global Pivotal Trial ...

Orchestra BioMed targeting enrollment completion of BACKBEAT Global Pivotal Trial ("BACKBEAT Trial") by the end of Q3 2026Medtronic (NYSE: MDT) and Orchestra BioMed intend to pursue late-breaking clin ...

Bank of America Global Healthcare Conference 2026 May 12, 2026 8:01 PM EDTCompany ParticipantsJeffrey Finer - Co-Founder, CEO ...

Discusses Strategic Focus on Izicopan for ANCA-Associated Vasculitis and Renal Diseases May 8, 2026 8:30 AM EDTCompany ...

Researchers have developed a chemoproteomics method using silyl ether chemistry to improve detection of small-molecule binding sites across the proteome. The approach enhances sensitivity, specificity ...